$Keros Therapeutics (KROS.US)$ Director ORBIMED ADVISORS LLC sold 250K shares of common stock on Aug 13, 2024 at an average price of $44.01 for a total value of $11 million.
This transaction involves other related parties: OrbiMed Capital GP VII LLC, OrbiMed Genesis GP LLC and GORDON CARL L.
What is statement of changes in beneficial ownership of securities?
It is a requirement under federal securities laws that mandates individuals, including officers, directors, and those who hold more than 10% of any class of a company's securities (collectively known as "insiders"), to report their purchases, sales, and holdings of their company's securities by submitting Forms 3, 4, and 5.
